gimli
GLAND stock analysis context
GLAND PHARMA Stock Context for AI Screening
GLAND PHARMA LIMITED is a mid-cap stock in Healthcare. This page summarizes key screening signals for GLAND PHARMA, including recent returns, momentum indicators, valuation ratios, liquidity, and growth metrics. Gimli uses this context to help users ask natural-language stock screening questions across Indian equities.
Ask Gimli about GLANDPrice
₹2,334.00
1M return
+29.62%
3M return
+28.12%
Market cap
₹38,454.14 cr
PE
44.29
ROE
+9.71%
RSI
78.07
Turnover
₹201.72 cr
Why it can matter in screens
- Momentum: GLAND is above 50DMA, above 200DMA; RSI is 78.07.
- Returns: 1M +29.62%, 3M +28.12%, 6M +28.97%.
- Liquidity: latest turnover is ₹201.72 cr.
- Valuation: PE 44.29, PB n/a, ROE +9.71%, ROCE +14.05%.
- Growth: 3Y sales CAGR +8.39%, 3Y profit CAGR -16.77%.
Try these prompts
- Analyze GLAND PHARMA with valuation, momentum and industry peers
- Compare GLAND with other Healthcare stocks
- Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View mid-cap stocks
- Find stocks above 50DMA
- Compare GLAND with other Healthcare stocks
Data snapshot: 2026-05-22. Not investment advice.